A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113

Conditions

Advanced Malignancies | Anaplastic Large Cell Lymphoma | Carcinoma, Non-Small-Cell Lung | Diffuse Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors

What is the purpose of this trial?


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Ariad Pharmaceuticals
Dates:
September 2011
Last Updated:
August 21, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01449461